You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 202261 - 202270 of 207712 results
  1. Validating Prodrug PRX-P4-003 approach in humans by phase 0 microdose study

    SBC: Praxis Biosciences            Topic: 101

    Binge Eating DisorderBEDis the most common eating disorder and carries an elevated risk of medical complications due to uncontrolled overeatingIt can be treated effectively with stimulantsbut their known abuse and diversion risk is a persistent concernOur strategic approach is to build on the proven efficacy of stimulants in BED while reducing abuse potentialThe goal of this Fast Track SBIR projec ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Validating Prodrug PRX-P4-003 approach in humans by phase 0 microdose study

    SBC: Praxis Biosciences            Topic: 101

    Binge Eating Disorder (BED) is the most common eating disorder and carries an elevated risk of medical complications due to uncontrolled overeating. It can be treated effectively with stimulants, but their known abuse and diversion risk is a persistent concern. Our strategic approach is to build on the proven efficacy of stimulants in BED while reducing abuse potential. The goal of this Fast-Track ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Validating the MicroKine Assay for Use in Identifying Personalized Precision Therapies for Pediatric Sepsis

    SBC: PreDxion Bio, Inc.            Topic: NICHD

    Project Summary Abstract PreDxion BioLLC is a precision medicine diagnostic company developing an assay platformthe MicroKineassay cartridge and readerthat measures serum proteins in less thanminutes from a single drop of bloodThis fastactionable information allows for the first time individualized precision medicine aimed at reducing pediatric morbidity and mortality in pediatric sepsisthe number ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Validating the performance and inclusivity of a novel functionally-informed predictive genetic test method for polygenic disease

    SBC: MARTINGALE LABS, INC.            Topic: 172

    PROJECT SUMMARY We now know that over 90% of causal variants for common diseases, including cardiovascular disease and many cancers, lie in non-coding regions of the genome. Therefore, a complete picture of common disease risk requires analyzing variants across the whole genome, not just the coding genome. Currently available methods to screen for common disease risk focus on monogenic coding vari ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Validating the Superiority of Ultra-Scan Score-Level Fusion

    SBC: Ultra-Scan Corporation            Topic: A10171

    Ultra-Scan will leverage the company's previously developed multimodal fusion technology to quantify the accuracy and validate the performance of its Neyman-Pearson fusion software for use with mission critical tactical identification systems, verifying that a score level fusion matching capability is achievable. A platform independent interface will be developed to allow integration of Ultra ...

    SBIR Phase I 2011 Department of DefenseArmy
  6. VALIDATION & TESTING OF THE VAM2D COMPUTER CODE

    SBC: Hydrogeologic Inc.            Topic: N/A

    SEVERAL STATES ARE CURRENTLY SEEKING MUCH-NEEDED NEW LOW-LEVEL RADIOACTIVE DISPOSAL SITES IN ACCORDANCE WITH THE LOW-LEVEL RADIOACTIVE WASTE POLICY ACT OF 1980. ANY NEW COMMERCIALREQUIREMENT THAT A SITE BE CAPABLE OF BEING MODELED AND THATITS PERFORMANCE BE ASSURED FOR 500 YEARS. FOR MOST SITES, THE HYDROGEOLOGICAL AND RADIONUCLIDE TRANSPORT CHARACTERIS- TICS OF THE UNSATURATED ZONE ARE MAJOR FACT ...

    SBIR Phase II 1989 Nuclear Regulatory Commission
  7. VALIDATION & TESTING OF THE VAM2D COMPUTER CODE

    SBC: Hydrogeologic Inc.            Topic: N/A

    N/A

    SBIR Phase I 1988 Nuclear Regulatory Commission
  8. Validation and commercialization of a/LCI for detection of esophageal neoplasia

    SBC: Oncoscope, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): The objective of this research is to commercialize a device (the Oncoscope Panocyte system) used to guide biopsy selection in patients with Barrett's esophagus (BE) during standard endoscopy surveillance for early- stage esophageal cancer. Barrett's esophagus most often develops in patients with chronic acid reflux and is the strongest risk factor fo ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  9. Validation and Cryopreservation of Ligament Engineered from Human Bone Marrow

    SBC: STEL Technologies, LLC            Topic: NIAMS

    DESCRIPTION provided by applicant The founders of Skeletal Tissue Engineering Laboratory Technologies LLC STEL are researchers at the University of Michigan Our research team has developed an innovative and paradigm shifting approach to ligament tissue engineering and a unique methodology for ACL replacement This tissue engineered ligament technology offers the possibility of radical impr ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Validation and development of specific small molecule inhibitors of HTRA1 for tre

    SBC: CALCYTE THERAPEUTICS, INC.            Topic: NEI

    DESCRIPTION (provided by applicant): Age-related macular degeneration (AMD) is the most common cause of visual impairment of the elderly in developed countries. Despite its prevalence with the aging population, its etiology and pathogenesis are poorly understood and the treatment options are limited. CalCyte's scientific co-founder, Kang Zhang, reported that polymorphisms in the promoter of the ge ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government